Eliem Therapeutics announces 2023 annual meeting voting results

Climb Bio, Inc.

Simon Tate elected as Class II director with 21,144,596 votes for, 555,897 withheld, 891,450 broker non-votes.
Ratification of PricewaterhouseCoopers as auditor: 22,574,271 for, 3,897 against, 13,775 abstentions.
Annual meeting held virtually on May 18, 2023; two proposals voted on.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Climb Bio, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-18 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-18

Exact text from the filing

Stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Climb Bio, Inc. shareholders approved Election of Class II director to serve until 2026 Annual Meeting at the 2023-05-18 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-18

Exact text from the filing

Stockholders elected the nominee for Class II director to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor has been duly elected and qualified.

View on SEC.gov

560 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-149424

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.